Kool group
Genomics, modeling and preclinical research of pediatric brain tumors
About our group
For more than two decades, Professor Marcel Kool and his team have been dedicated to improving the understanding and treatment of pediatric brain tumors. The group was established in 2011 at the German Cancer Research Center (DKFZ) and Hopp Children's Cancer Center Heidelberg (KiTZ), and has been based at the Prinses Máxima Centrum since 2019. Early 2026, our research activities in Heidelberg were discontinued.
Over the years, our group has made important contributions to the molecular classification of pediatric brain tumors, helping to redefine how these diseases are diagnosed and understood. Their research has identified new tumor types and subgroups, uncovered the biological mechanisms that drive tumor development, and developed laboratory models that better reflect tumors in children. These discoveries have laid the foundation for more precise diagnoses and the development of new, targeted treatment strategies. Today, the group continues to build on this expertise, with the goal of translating biological insights into safer and more effective therapies for children with brain tumors.
Contact

Marcel Kool
Focus on embryonal brain tumors and ependymoa
Our research focuses on some of the most challenging childhood brain tumors, including ependymoma and embryonal brain tumors such as medulloblastoma, atypical teratoid/rhabdoid tumor (ATRT), embryonal tumor with multilayered rosettes (ETMR), and rare embryonal and sarcomatous tumors of the CNS. The latter includes CNS tumors with BCOR alterations (CNS-BCOR) and astroblastoma, MN1-altered. Together, these tumors account for about aproportion of malignant brain tumors in children and often require intensive treatment.
While survival has improved for some tumor types, many children still have a poor prognosis or experience lifelong side effects from current therapies. For several of the rarer tumor types, there is no established standard of care, and prospective clinical trials are scarce or absent, leaving patients with few evidence-based treatment options. Our goal is to better understand the biology of these tumors, uncover the molecular mechanisms that drive their growth, and identify new therapeutic vulnerabilities. By combining molecular profiling, advanced preclinical models, and translational research, we aim to accelerate the development of more precise, effective, and less toxic treatments, and to generate the biological evidence needed to support future clinical trials for children with these rare brain tumors.
“We study the genomics and single cell transcriptomics of pediatric brain tumors and how to translate findings from these studies into novel therapies using preclinical models”
Marcel Kool
Research group leader
Molecular and cellular characterisation
A major focus of our research is to understand the molecular characteristics and mechanisms that drive childhood brain tumors. Over the past decade, our group has helped transform the classification of pediatric brain tumors through large-scale genomic and epigenomic studies. By analysing DNA, RNA, DNA methylation patterns, and more recently single-cell and single-nucleus RNA sequencing data, we aim to understand how these tumors develop, what the cellular composition of the tumor and the tumor (immune) microenvironment is, why they behave differently, and how they can be treated more effectively.
In recent years, our research has provided new insights into several pediatric brain tumor types. We have contributed to refining the molecular classification of medulloblastoma, ATRT and ependymoma, identified distinct biological types and subtypes of rare embryonal tumors, and helped characterize newly recognized tumor entities such as astroblastoma, MN1-altered and CNS-BCOR.
Through single-cell transcriptomic analyses, we have uncovered the cellular composition and developmental origins of medulloblastoma, ETMR, ATRT, and ependymoma, revealing interactions between tumor cells and their microenvironment and identifying pathways that may be exploited therapeutically.
Advanced models for pediatric brain tumors
Developing better therapies requires laboratory models that faithfully represent the complexity of childhood brain tumors. Our group develops and applies a wide range of preclinical model systems, including patient-derived xenografts (PDXs), patient-derived tumoroids, and genetically engineered brain tumor organoids. With these models, we hope to preserve and better mimic the biological and molecular characteristics of patients' tumors and allow us to study tumor biology, discover new therapeutic targets, and evaluate promising drugs before they enter clinical trials.
Our work has contributed to the development of one of the world's largest collections of molecularly characterized pediatric cancer PDX models through the international ITCC-P4 consortium. This unique resource enables researchers to select the most representative models for specific tumor subtypes and provides a powerful platform for preclinical testing of new therapies across high-risk pediatric cancers.
Together with other groups at the Princess Máxima Center, we are generating brain tumor organoids (BTOs). These are 3D cultures of tumors from our patients. This BTO approach has advantages over other approaches. Compared to normal 2D cell culture techniques, these BTOs better represent the original tumor and its heterogeneity. It also allows a more high-throughput approach than using tumor xenografts in mice. Our current collection include medulloblastoma, ETMR and CNS-BCOR BTO lines, which are being used in drug screens to investigate whether the tumor might be sensitive for FDA approved drugs and new drug candidates.
To better study tumorigenesis or to generate models for which we have not yet generated BTOs, we also use brain organoids. These organoids resemble the developing brain tissue and thereby contains the neural progenitor cells from which ependymoma and embryonal tumors arise. By introducing oncodriving events into these brain organoids, we can induce tumorigenesis. For example, we recently established genetically engineered cerebral organoid models of YAP1- and ZFTA-fusion ependymoma, demonstrating that these tumors can be faithfully modeled from their presumed cells of origin. These models provide unprecedented opportunities to study the earliest stages of tumor formation, investigate the biology of different ependymoma subtypes, and identify novel treatment strategies.
By integrating these complementary model systems with molecular and functional analyses, we aim to bridge the gap between discoveries in the laboratory and new treatment options for children with brain tumors.
Grants and publications
Information about our group
Our research group, headed by Professor Marcel Kool together with Dr Jens Bunt, currently consists of five PhD students, two Postdocs, two Research Technicians and a project managers.
Our group is currently hosting three students for their MSc internship:
Vasilis Papageorgiou (MSc Bioinformatics and Biocomplexity program at Utrecht University). He is working together with Álvaro.
Lola Démurger ((MSc Molecular and Cellular Life Sciences program at Utrecht University). She is working together with Francesco.
Adam Donovan MSc Regenerative Medicine & Technology at Utrecht University). He is working together with Julie.
Within the next months, we will be recruiting an additional Postdoc for molecular characterisation of astroblastoma. We currently have no positions for PhD students available. For internship opportunities, please read section below.
Internship oppertunities
The Kool group is often hosting students as interns for their Bachelor or Master projects, literature assignments or exchange scholarships. We currently have no opportunities till mid 2027 for any students seeking laboratory or bioinformatic projects. We may consider may consider literature study assignments, Erasmus scholarships or other funded student exchange programs for early 2027 and onwards. If you are interested in an internship in our group, please contact Jens Bunt via email. Ensure to provide your motivation, CV and preferred period in the email. Please note that we only consider students for projects with a minimal duration of six months.
Join us
To cure every child with cancer, we are looking for the best scientists! Working in a top organization demands highly qualified employees who perform to their utmost in a work environment with continuous motivation for improvement. Do you recognize yourself in our core values as groundbreaking and passionate? Explore the job opportunities in our research department.
Explore job opportunities